Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Gravanis I, Ersbøll J, Skovlund E, Abadie E, Marty M, Pignatti F. Gravanis I, et al. Among authors: pignatti f. Oncologist. 2010;15(12):1335-43. doi: 10.1634/theoncologist.2010-0255. Epub 2010 Dec 14. Oncologist. 2010. PMID: 21156732 Free PMC article.
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F. Matt P, et al. Among authors: pignatti f. Oncologist. 2011;16(10):1451-7. doi: 10.1634/theoncologist.2011-0224. Epub 2011 Sep 30. Oncologist. 2011. PMID: 21963999 Free PMC article. Review.
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F. Pean E, et al. Among authors: pignatti f. Oncologist. 2012;17(4):543-9. doi: 10.1634/theoncologist.2011-0364. Epub 2012 Apr 3. Oncologist. 2012. PMID: 22477727 Free PMC article. Review.
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F. Pean E, et al. Among authors: pignatti f. Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24. Clin Cancer Res. 2012. PMID: 22829199
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F. da Rocha Dias S, et al. Among authors: pignatti f. Eur J Cancer. 2013 May;49(7):1654-61. doi: 10.1016/j.ejca.2013.01.015. Epub 2013 Mar 5. Eur J Cancer. 2013. PMID: 23481513
The European Medicines Agency approval of 5-aminolaevulinic acid (Ameluz) for the treatment of actinic keratosis of mild to moderate intensity on the face and scalp: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Tzogani K, Straube M, Hoppe U, Kiely P, O'Dea G, Enzmann H, Salmon P, Salmonson T, Pignatti F. Tzogani K, et al. Among authors: pignatti f. J Dermatolog Treat. 2014 Oct;25(5):371-4. doi: 10.3109/09546634.2013.789474. Epub 2013 May 21. J Dermatolog Treat. 2014. PMID: 23550714 Free article. Clinical Trial.
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
Péan E, Flores B, Hudson I, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. Péan E, et al. Among authors: pignatti f. Oncologist. 2013;18(5):625-33. doi: 10.1634/theoncologist.2013-0020. Epub 2013 Apr 24. Oncologist. 2013. PMID: 23615696 Free PMC article.
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
Gravanis I, Lopez AS, Hemmings RJ, Jiménez JC, Garcia-Carbonero R, Gallego IG, Giménez EV, O'Connor D, Giuliani R, Salmonson T, Pignatti F. Gravanis I, et al. Among authors: pignatti f. Oncologist. 2013;18(9):1032-42. doi: 10.1634/theoncologist.2013-0092. Epub 2013 Aug 21. Oncologist. 2013. PMID: 23966222 Free PMC article.
The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z, Unkrig C, Enzmann H, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. Hanaizi Z, et al. Among authors: pignatti f. Oncologist. 2014 Apr;19(4):421-5. doi: 10.1634/theoncologist.2013-0294. Epub 2014 Mar 25. Oncologist. 2014. PMID: 24668331 Free PMC article.
133 results